Xorte logo

News Markets Groups

USA | Europe | Asia | World| Stocks | Commodities



Add a new RSS channel

 
 


Keywords

2023-05-26 02:15:41| Engadget

Turns out Elon Musk's FDA prediction was only off by about a month. After reportedly denying the company's overtures in March, the FDA approved Neuralink's application to begin human trials of its prototype Link brain-computer interface (BCI) on Thursday. Founded in 2016, Neuralink aims to commercialize BCIs in wide-ranging medical and therapeutic applications from stroke and spinal cord injury (SCI) rehabilitation, to neural prosthetic controls, to the capacity "to rewind memories or download them into robots," Neuralink CEO Elon Musk promised in 2020. BCIs essentially translate the analog electrical impulses of your brain (monitoring it using hair-thin electrodes delicately threaded into that grey matter) into the digital 1's and 0's that computers understand. Since that BCI needs to be surgically installed in a patient's noggin, the FDA which regulates such technologies requires that companies conduct rigorous safety testing before giving its approval for commercial use. In March, the FDA rejected Neuralink's application to begin human trials reportedly in part due to all the test animals that kept dying after having the prototype BCI implanted. According to internal documents acquired by Reuters in December, more than 1,500 animals had been killed in the development of the Neuralink BCI since 2018. The US Department of Agriculture's (USDA) Inspector General has since launched an investigation into those allegations.  The FDA's reticence was also born from concerns about the design and function of the interface when implanted in humans. "The agencys major safety concerns involved the devices lithium battery; the potential for the implants tiny wires to migrate to other areas of the brain; and questions over whether and how the device can be removed without damaging brain tissue," current and former Neuralink employees told Reuters in March.While Neuralink has obtained FDA approval to begin its study, the company is not yet seeking volunteers. This is the result of incredible work by the Neuralink team in close collaboration with the FDA and represents an important first step that will one day allow our technology to help many people," Neuralink Tweeted on Thursday. "Recruitment is not yet open for our clinical trial."  This article originally appeared on Engadget at https://www.engadget.com/neuralink-receives-fda-clearance-to-begin-human-trials-of-its-brain-computer-interface-001504243.html?src=rss


Category: Marketing and Advertising

 

Latest from this category

19.04Fallout has already scored a green light for a second season
19.04Baldur's Gate 3 developer confirms it won't make the sequel
19.04Apple says it was ordered it to remove WhatsApp and Threads from China App Store
19.04Surprise: Taylor Swift is joining Threads on the day her new album drops
19.04The bill that could ban TikTok is barreling ahead
18.04Netflix is done telling us how many people use Netflix
18.04Blizzard takes aim at Overwatch 2 console cheaters
18.04Amazon no longer offers its easy-to-miss Prime Video subscription
Marketing and Advertising »

All news

19.04United States: The Pregnant Workers Fairness Act: EEOC Issues Final Regulations - Ogletree, Deakins, Nash, Smoak & Stewart
19.04United States: CMS Finalizes CY 2025 Medicare Advantage Rule, Confirming Continued Focus On Marketing Practices And Health Equity - Bass, Berry & Sims
19.04United States: Supreme Court Finds FAA 'Transportation Worker' Exemption Does Not Require Employment In Transportation Industry - Greenberg Traurig, LLP
19.04United States: Effective June 12, California Issues Final Regulations For Charitable Fundraising Platforms Registration Duty For Cause-Marketing Programs - Greenberg Traurig, LLP
19.04United States: Tax Court Rejects Constitutional Challenges To International Information Return Penalties - Greenberg Traurig, LLP
19.04United States: Southeast Litigation Update: February 2024 - Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
19.04Canada: Matters To Consider For The 2024 Annual General Meeting And Proxy Season - Lawson Lundell LLP
19.04United States: Supreme Court Clarifies FAA Arbitration Exception Not Limited To Transportation Workers - McGlinchey Stafford
More »
Privacy policy . Copyright . Contact form .